These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 1740520)
21. Assessment of the activation pathways of the complement in psoriatic patients by use of complement fragment C4d and Bb measurements. Takematsu H; Tagami H Dermatologica; 1989; 179 Suppl 1():16-9. PubMed ID: 2789155 [TBL] [Abstract][Full Text] [Related]
22. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Abramson SB; Buyon JP Am J Reprod Immunol; 1992; 28(3-4):183-7. PubMed ID: 1285875 [TBL] [Abstract][Full Text] [Related]
23. Complement activation before, during and after cardiopulmonary bypass. Bonser RS; Dave JR; John L; Gademsetty MK; Carter PG; Davies E; Taylor P; Gaya H; Lennox SC; Vergani D Eur J Cardiothorac Surg; 1990; 4(6):291-6. PubMed ID: 2361017 [TBL] [Abstract][Full Text] [Related]
24. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Buyon JP; Cronstein BN; Morris M; Tanner M; Weissmann G Am J Med; 1986 Aug; 81(2):194-200. PubMed ID: 3740078 [TBL] [Abstract][Full Text] [Related]
25. Rocket immunoelectrophoresis of C4 and C4d. A simple sensitive method for detecting complement activation in plasma. Nitsche JF; Tucker ES; Sugimoto S; Vaughan JH; Curd JG Am J Clin Pathol; 1981 Nov; 76(5):679-84. PubMed ID: 6794354 [TBL] [Abstract][Full Text] [Related]
26. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Yang DH; Chang DM; Lai JH; Lin FH; Chen CH Rheumatology (Oxford); 2009 Sep; 48(9):1083-7. PubMed ID: 19553377 [TBL] [Abstract][Full Text] [Related]
28. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy. Yamada T; Moroo I; Koguchi Y; Asahina M; Hirayama K Acta Neurol Scand; 1994 Jan; 89(1):42-6. PubMed ID: 8178627 [TBL] [Abstract][Full Text] [Related]
29. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588 [TBL] [Abstract][Full Text] [Related]
30. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444 [TBL] [Abstract][Full Text] [Related]
31. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients. Boeckler P; Meyer A; Uring-Lambert B; Goetz J; Cribier B; Hauptmann G; Lipsker D Clin Immunol; 2006 Nov; 121(2):198-202. PubMed ID: 16987709 [TBL] [Abstract][Full Text] [Related]
32. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus. Li J; An L; Zhang Z Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509 [TBL] [Abstract][Full Text] [Related]
33. Activation of the classical complement pathway in spontaneous bacterial peritonitis. Bird G; Senaldi G; Panos M; Rolando N; Alexander G; Vergani D; Williams R Gut; 1992 Mar; 33(3):307-11. PubMed ID: 1568647 [TBL] [Abstract][Full Text] [Related]
34. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Buyon JP; Tamerius J; Belmont HM; Abramson SB Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018 [TBL] [Abstract][Full Text] [Related]
35. Complement activation products in idiopathic pulmonary fibrosis: relevance of fragment Ba to disease severity. Meliconi R; Senaldi G; Sturani C; Galavotti V; Facchini A; Gasbarrini G; Vergani D Clin Immunol Immunopathol; 1990 Oct; 57(1):64-73. PubMed ID: 2394036 [TBL] [Abstract][Full Text] [Related]
36. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Gupta N; Wakefield DN; Clapp WL; Garin EH Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516 [TBL] [Abstract][Full Text] [Related]
37. Preparation of antibodies against the fourth complement component (C4) and development of a direct electroimmunoassay for quantification of C4d. Folkersen J; Teisner B; Petersen NE; Sim RB; Jessen E J Clin Lab Immunol; 1985 Mar; 16(3):163-7. PubMed ID: 4032454 [TBL] [Abstract][Full Text] [Related]
38. Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia. Penning M; Chua JS; van Kooten C; Zandbergen M; Buurma A; Schutte J; Bruijn JA; Khankin EV; Bloemenkamp K; Karumanchi SA; Baelde H Hypertension; 2015 Jul; 66(1):117-25. PubMed ID: 25941343 [TBL] [Abstract][Full Text] [Related]
39. Activation of the alternative pathway of complement in psoriatic lesional skin. Takematsu H; Tagami H Dermatologica; 1990; 181(4):289-92. PubMed ID: 2073958 [TBL] [Abstract][Full Text] [Related]
40. Activation of the fourth component of complement (C4): assessment by rocket immunoelectrophoresis and correlation with the metabolism of C4. Milgrom H; Curd JG; Kaplan RA; Müller-Eberhard HJ; Vaughan JH J Immunol; 1980 Jun; 124(6):2780-5. PubMed ID: 7373050 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]